EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Navigating CAR-T translation in Australia: lessons from an academic program

Rui Ping Amanda Tan, Robyn Walsh, Geoffrey McCowage, Geraldine M O'Neill, Kavitha Gowrishankar

Frontiers in Medicine · 10.08.2026 · 13

DOI: 10.3389/fmed.2026.1920197 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Medicine, online erschienen am 10.08.2026. Verfasst von Rui Ping Amanda Tan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Research Unit, The Children's Hospital Westmead, Sydney Children Hospitals Network, Sydney, NSW, Australia. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive cell therapies utilizing both gene-modified and unmodified immune cells have revolutionized treatments for cancer and infection. Seven Chimeric antigen receptor (CAR) T cell products have been approved as therapies, providing the momentum to expand their clinical benefit to several cancer types. Many novel receptor-expressing cell therapies remain in preclinical development and require robust clinical testing Translating these into early-phase clinical trials requires navigating manufacturing, quality, and regulatory systems that are often not documented explicitly for academic investigators. This manuscript provides a stage-by-stage roadmap for translating academic CAR T-cell research into an investigator-led Phase I clinical trial in the Australian public sector. It draws on the E2CAR program, the first clinical translation of an EphA2-directed CAR T-cell product into pediatric bone sarcoma, conducted at the Children’s Hospital at Westmead. We present our experience across six stages: construct finalization and vector strategy, manufacturing process development, quality infrastructure, assay development and validation, multi-entity operational coordination, and CTA regulatory engagement and provide recommendations for researchers at each stage. We also present a consolidated program timeline, minimum personnel requirements, and indicative costs to support grant applications and institutional planning. While the operational framework described here was developed specifically for our Health Precinct some of the recommendations we provide are likely to benefit academic groups navigating constraints in comparable settings.

Schlagwörter

Stichwörter der Autor:innen

CAR - T therapyguidelinesinvestigator led trialregulatory approvaltranslation

Autor:innen und Institutionen

  • Children's Cancer Research Unit, The Children's Hospital Westmead, Sydney Children Hospitals Network, Sydney, NSW, Australia.
  • Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.

Zitieren

APA

Tan, R. P. A., Walsh, R., McCowage, G., O'Neill, G. M., & Gowrishankar, K. (2026). Navigating CAR-T translation in Australia: lessons from an academic program. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1920197

Vancouver

Tan RPA, Walsh R, McCowage G, O'Neill GM, Gowrishankar K. Navigating CAR-T translation in Australia: lessons from an academic program. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1920197

BibTeX
@article{Tan2026,
  author = {Tan, Rui Ping Amanda and Walsh, Robyn and McCowage, Geoffrey and O'Neill, Geraldine M and Gowrishankar, Kavitha},
  title = {Navigating CAR-T translation in Australia: lessons from an academic program},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1920197}
}
Kostenlos starten →